Unknown PHASE1/PHASE2 INTERVENTIONAL 10-arm NCT03607643

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

Randomized Double-Blind, Placebo-Controlled Parallel Multi-Center Study to Assess the Efficacy of Cannabidiol (BRCX014) Combined With Standard-Of-Care Treatment in Subjects With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

Sponsor: Leaf Vertical Inc.

Conditions Cancer of Colon Cancer of Liver Cancer of Pancreas Cancer of Rectum Cancer, Gall Bladder Glioblastoma Multiforme Myeloma Multiple

Interventions 5-FU Bevacizumab Bortezomib Cannabidiol Gemcitabine Irinotecan Leucovorin Oxaliplatin Temozolomide

Updated 4 times since 2018 Last updated: Jul 22, 2018 Started: Jan 15, 2019 Primary completion: Jun 30, 2020 Completion: Dec 15, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03607643, this PHASE1/PHASE2 trial focuses on Cancer of Colon and Cancer of Liver and remains ongoing. Sponsored by Leaf Vertical Inc., it has been updated 4 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Not Yet Recruiting → Unknown Status
Aug 2018 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Leaf Vertical Inc.

Data source: Leaf Vertical Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Orlando, United States